A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2011
The objective of this study is to compare the progression free survival (PFS), overall survival (OS), objective response rate (ORR), time to treatment failure (TTF), duration of response (DoR), quality of life, safety and tolerability of tivozanib in combination with mFOLFOX6 and bevacizumab in combination with mFOLFOX6.
Epistemonikos ID: be0956dd2a66bebf12014e964a57b735ff35214d
First added on: May 10, 2024